KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Astrazeneca (AZN) over the last 17 years, with Q4 2025 value amounting to $114.1 billion.

  • Astrazeneca's Liabilities and Shareholders Equity rose 964.96% to $114.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $447.2 billion, marking a year-over-year increase of 760.73%. This contributed to the annual value of $114.1 billion for FY2025, which is 964.96% up from last year.
  • Latest data reveals that Astrazeneca reported Liabilities and Shareholders Equity of $114.1 billion as of Q4 2025, which was up 964.96% from $114.5 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Liabilities and Shareholders Equity ranged from a high of $114.5 billion in Q3 2025 and a low of $104.0 million during Q4 2021
  • In the last 5 years, Astrazeneca's Liabilities and Shareholders Equity had a median value of $100.7 billion in 2022 and averaged $94.3 billion.
  • In the last 5 years, Astrazeneca's Liabilities and Shareholders Equity tumbled by 9979.68% in 2021 and then skyrocketed by 9267211.54% in 2022.
  • Quarter analysis of 5 years shows Astrazeneca's Liabilities and Shareholders Equity stood at $104.0 million in 2021, then skyrocketed by 92672.12% to $96.5 billion in 2022, then increased by 4.8% to $101.1 billion in 2023, then grew by 2.88% to $104.0 billion in 2024, then grew by 9.65% to $114.1 billion in 2025.
  • Its last three reported values are $114.1 billion in Q4 2025, $114.5 billion for Q3 2025, and $112.4 billion during Q2 2025.